RxDoctor Payments Data

Ravi Bhatia, DO

Nephrology · Canton, GANPI 1508211376

Payments from drug & device makers

$3,599in general payments, 2019–2025

Across 127 payments — averaging $28.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$559
  • Travere Therapeutics, Inc.$423
  • Calliditas Therapeutics US Inc.$352
  • Mallinckrodt Hospital Products Inc.$340
  • Otsuka America Pharmaceutical, Inc.$246
  • plus $549 from 12 others

What the payments were for

  • Consulting fees$2256%
  • Travel & lodging$66919%
  • Food & beverage$2,49269%
  • Education$2146%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,599 in reported general payments places this provider in the 65th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$199,503
Medicare patients
452
Services billed
3,279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol66$49,251
XareltoRivaroxaban14$9,726
MyrbetriqMirabegron19$9,378
Calcitriol118$2,159
Calcium Acetate13$1,472
Nifedipine ErNifedipine54$1,405
Sevelamer Carbonate11$1,360
Hydralazine Hcl61$1,274
Torsemide57$1,233
Valsartan55$1,191
Carvedilol77$1,169
Losartan Potassium89$879
Bumetanide21$615
Chlorthalidone40$556
Amlodipine Besylate93$554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,130$49,25166 claims
ANI Pharmaceuticals, Inc.Valsartan$19$1,19155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 nephrology providers in Georgia.

Other nephrology in Canton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →